SF 1019

Drug Profile

SF 1019

Alternative Names: R-1818; SF-1019

Latest Information Update: 10 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argyll Biotechnologies LLC
  • Developer Argyll Biotechnologies
  • Class Anti-inflammatories; Lipoproteins; Non-opioid analgesics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Inflammation; Skin ulcer

Most Recent Events

  • 13 Aug 2008 Registered for Diabetic neuropathies in Malaysia (SC)
  • 13 Aug 2008 Registered for Inflammation in Malaysia (SC)
  • 13 Aug 2008 Registered for Skin ulcer in Malaysia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top